Jiangsu Hengrui Shifts From Generic Supplier To Innovative Company; Analysts See Shades Of Takeda In Transformation
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Jiangsu Hengrui Medicine Co. Ltd. seeks to transform itself from a generic company to an innovative one and tap into overseas markets. The move has prompted Chinese analysts to draw comparisons to the business models of Japan's largest pharma and to predict that Jiangsu Hengrui could become China's version of Takeda Pharmaceutical Co. Ltd.
You may also be interested in...
China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences
Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.
China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences
Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.
Chinese Local Pharmas See Innovative Products As Future Growth Driver - China Healthcare Investment Conference
BEIJING - Fueled by the Chinese government's latest five-year plan that will promote innovation and increase exports of finished products, Chinese domestic companies are increasing their R&D efforts to ensure future growth, companies said during the second annual China Healthcare Investment conference March 23